Diagnostic imaging of primary hepatic neuroendocrine tumors and treatment with transarterial chemoembolization: analysis of 6 cases
10.3760/cma.j.issn.1007-3418.2018.04.012
- VernacularTitle: 肝脏原发性神经内分泌肿瘤影像学诊断与肝动脉化学治疗栓塞术治疗6例分析
- Author:
Xiaoshuai LI
1
;
Mengchao ZHANG
;
Yangchun QU
;
Xiaoqian ZHANG
;
Feng PAN
;
Yunxia LIU
Author Information
1. Department of Radiology, the Chinese-Japan Union Hospitai of Jilin University, Changchun 130033, China
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Diagnosis;
Interventional therapy
- From:
Chinese Journal of Hepatology
2018;26(4):294-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the imaging diagnosis, treatment and prognosis of primary hepatic neuroendocrine tumors.
Methods:The clinical features, imaging manifestations, histopathological and immunohistochemical findings and interventional therapy of 6 patients identified with pathologically confirmed primary hepatic neuroendocrine tumors were retrospectively analyzed, and the related literatures were reviewed.
Results:All 6 patients presented with symptoms of abdominal pain. 4 patients had solitary hepatic mass and 2 patients had multiple hepatic masses. Magnetic resonance imaging showed low signal intensity on T1 weighted imaging, high signal intensity on T2 weighted imaging and clear boundary; the arterial phase of enhancement scan was uneven and enhanced, and portal venous phase or delayed phase showed continuous enhancement, surrounded by ring enhanced capsule. A pathological diagnosis was primary neuroendocrine tumor of the liver. After interventional treatment, 6 patients had some therapeutic effects. Among them, 4 patients underwent multiple interventional therapies, followed by 4 years of follow-up has shown satisfactory results.
Conclusion:Primary hepatic neuroendocrine tumors are very rare and their imaging manifestations are specific. Eventually, relies on pathological and immunohistochemical diagnosis. Transarterial chemoembolization therapy can bring satisfactory results in the treatment of primary hepatic neuroendocrine tumor.
